Tizanidine
Product Images NDC 53002-1437

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 53002-1437). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Molecular Structure (Ee6ccf71 79ba 43ca 9a1a 1cab1d5a0c6c 01)

Chemical structure diagram of the active ingredient Tizanidine hydrochloride, showing its molecular connectivity including a chlorinated aromatic ring and heterocyclic components.*

FDA Label Image

Figure-1 (Ee6ccf71 79ba 43ca 9a1a 1cab1d5a0c6c 02)

A pharmacokinetic line graph depicting plasma concentration of Tizanidine (ng/mL) over time in hours after dosing. The graph compares four groups: 2x 4 mg Tizanidine tablets with food, 2x 4 mg tablets without food, 2x 4 mg capsules with food, and 2x 4 mg capsules without food. Concentration peaks around 1-2 hours before declining.*

FDA Label Image

Figure 3 (Ee6ccf71 79ba 43ca 9a1a 1cab1d5a0c6c 03)

Line graph showing the improvement in Ashworth Score over time (hours post-dose) for three groups: 16 mg tizanidine, 8 mg tizanidine, and placebo. The graph includes error bars depicting variability at each time point from 0 to 6 hours post-dose. The 16 mg dose shows the highest improvement, followed by 8 mg, with placebo showing minimal change.*

FDA Label Image

Figure 4 (Ee6ccf71 79ba 43ca 9a1a 1cab1d5a0c6c 04)

A line graph depicting improvement in Ashworth Score over time at three study points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carry Forward). Two groups are compared: tizanidine (mean dose 28.8 mg) and placebo, with the tizanidine group showing greater improvement scores at each time point.*

FDA Label Image

Logo (Ee6ccf71 79ba 43ca 9a1a 1cab1d5a0c6c 05)

FDA Label Image

Label Image (Lbl530021437)

Tizanidine 4 mg tablets label from RPK Pharmaceuticals, Inc. This prescription drug label indicates each tablet contains 4 mg of tizanidine, is in a 30-tablet bottle, and advises patients to take 1 tablet three times daily or as directed. The label includes drug and manufacturer details along with dosage instructions and lot/expiration information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.